公开(公告)号：US10577403B2

公开(公告)日：2020-03-03

申请号：US16438735

申请日：2019-06-12

Applicant: ModernaTX, Inc.

Inventor： Antonin De Fougerolles ,  Justin Guild

IPC: A61K48/00 ,  A61K38/17 ,  A61K47/54 ,  A61K9/127 ,  C07K14/535 ,  A61K31/7088 ,  A61K38/48 ,  C07K14/745 ,  C07K16/28 ,  C07K16/32 ,  C12N9/02 ,  C12N9/64 ,  A61K38/19 ,  A61K38/21 ,  A61K38/36 ,  A61K38/44 ,  A61K39/395 ,  C07K14/475 ,  C07K14/505 ,  C07K14/525 ,  C07K14/56 ,  C07K14/565 ,  C07K14/75 ,  A61K47/10 ,  A61K38/18 ,  A61K9/14 ,  C07K14/47 ,  C12N15/85 ,  A61K9/50 ,  C12N15/88 ,  C07K19/00 ,  A61K31/7115 ,  C07K14/005 ,  C12N15/11 ,  C12N9/00 ,  A61K9/00

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

公开(公告)号：US10703789B2

公开(公告)日：2020-07-07

申请号：US16438978

申请日：2019-06-12

Applicant: ModernaTX, Inc.

Inventor： Antonin De Fougerolles ,  Justin Guild

IPC: A61K48/00 ,  A61K38/17 ,  A61K47/54 ,  A61K9/127 ,  C07K14/535 ,  C12N15/88 ,  A61K9/50 ,  C07K14/47 ,  A61K31/7088 ,  C07K19/00 ,  C12N15/85 ,  A61K38/18 ,  A61K38/19 ,  A61K38/48 ,  A61K9/14 ,  A61K47/10 ,  A61K38/21 ,  A61K38/36 ,  A61K38/44 ,  A61K39/395 ,  C07K14/475 ,  C07K14/505 ,  C07K14/525 ,  C07K14/56 ,  C07K14/565 ,  C07K14/745 ,  C07K14/75 ,  C07K16/28 ,  C07K16/32 ,  C12N9/02 ,  C12N9/64 ,  A61K31/7115 ,  C07K14/005 ,  C12N15/11 ,  C12N9/00 ,  A61K9/00

Abstract: A pharmaceutical composition which has a plurality of lipid nanoparticles that has a mean particle size of between 80 nm and 160 nm and contains a modified mRNA encoding a polypeptide. The lipid nanoparticles include a cationic lipid, a neutral lipid, a cholesterol, and a PEG lipid. The mRNA contains a 5′-cap, 5′-UTR, N1-methyl-pseudouridine, a 3′-UTR, and a poly-A region with at least 100 nucleotides.

公开(公告)号：US20170348436A1

公开(公告)日：2017-12-07

申请号：US15403517

申请日：2017-01-11

Applicant: ModernaTX, Inc.

Inventor： Stephane Bancel ,  Tirtha Chakraborty ,  Antonin de Fougerolles ,  Sayda M. Elbashir ,  Matthias John ,  Atanu Roy ,  Susan Whoriskey ,  Kristy M. Wood ,  Paul Hatala ,  Jason P. Schrum ,  Kenechi Ejebe ,  Jeff Lynn Ellsworth ,  Justin Guild

IPC: A61K48/00 ,  A61K9/127 ,  C12P21/00 ,  C12P13/04 ,  C12N15/87 ,  C12N15/85 ,  C12N15/52 ,  C12N15/11 ,  C12N9/00 ,  C12N9/88 ,  C12N9/64 ,  C12N9/42 ,  C12N9/24 ,  C12N9/16 ,  C12N9/10 ,  C07K16/00 ,  C07K14/705 ,  C07K14/62 ,  C07K14/56 ,  C07K14/535 ,  C07K14/525 ,  C07K14/515 ,  C07K14/505 ,  A61K47/54 ,  C07K14/47 ,  C07K14/435 ,  C07K14/005 ,  A61K38/48 ,  A61K38/45 ,  A61K38/21 ,  A61K38/19 ,  A61K38/18 ,  A61K38/17 ,  A61K31/7115 ,  A61K9/51 ,  A61K9/14 ,  C07K14/485 ,  A61K38/00

CPC classification number: A61K48/0066 ,  A61K9/1271 ,  A61K9/145 ,  A61K9/5123 ,  A61K9/5146 ,  A61K9/5153 ,  A61K31/7115 ,  A61K38/00 ,  A61K38/17 ,  A61K38/177 ,  A61K38/1816 ,  A61K38/1891 ,  A61K38/191 ,  A61K38/193 ,  A61K38/212 ,  A61K38/45 ,  A61K38/4846 ,  A61K47/543 ,  A61K48/0033 ,  A61K48/005 ,  A61K48/0075 ,  C07H21/02 ,  C07K14/005 ,  C07K14/435 ,  C07K14/43595 ,  C07K14/47 ,  C07K14/4705 ,  C07K14/4713 ,  C07K14/4723 ,  C07K14/4746 ,  C07K14/475 ,  C07K14/485 ,  C07K14/495 ,  C07K14/505 ,  C07K14/515 ,  C07K14/525 ,  C07K14/535 ,  C07K14/5418 ,  C07K14/56 ,  C07K14/61 ,  C07K14/62 ,  C07K14/705 ,  C07K14/745 ,  C07K16/00 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/40 ,  C12N9/0069 ,  C12N9/0091 ,  C12N9/1051 ,  C12N9/1241 ,  C12N9/16 ,  C12N9/2402 ,  C12N9/2445 ,  C12N9/6435 ,  C12N9/6437 ,  C12N9/644 ,  C12N9/6443 ,  C12N9/6451 ,  C12N9/88 ,  C12N9/93 ,  C12N15/11 ,  C12N15/52 ,  C12N15/85 ,  C12N15/87 ,  C12P13/04 ,  C12P21/00 ,  C12P21/005 ,  C12Y113/12007 ,  C12Y116/03001 ,  C12Y207/07012 ,  C12Y304/21007 ,  C12Y304/21022 ,  C12Y304/21027 ,  C12Y403/02001 ,  C12Y603/02019 ,  Y02A50/401 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/415 ,  Y02A50/423 ,  Y02A50/463 ,  Y02A50/491

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

公开(公告)号：US09814760B2

公开(公告)日：2017-11-14

申请号：US14878400

申请日：2015-10-08

Applicant: ModernaTX, Inc.

Inventor： Stephane Bancel ,  Tirtha Chakraborty ,  Antonin de Fougerolles ,  Sayda M. Elbashir ,  Matthias John ,  Atanu Roy ,  Susan Whoriskey ,  Kristy M. Wood ,  Paul Hatala ,  Jason P. Schrum ,  Kenechi Ejebe ,  Jeff Lynn Ellsworth ,  Justin Guild

IPC: C07H21/02 ,  C12N15/85 ,  A61K38/17 ,  C07K14/47 ,  C07K14/62 ,  A61K48/00 ,  A61K31/7115 ,  C12N9/88 ,  A61K9/127 ,  C12N15/11 ,  C07K14/705 ,  C07K14/505 ,  C07K14/535 ,  C12N9/64 ,  C12N9/10 ,  C12N9/00 ,  C12N9/42 ,  C12N15/87 ,  C12P13/04 ,  A61K38/45 ,  C07K14/005 ,  C12N9/16 ,  C12N9/24 ,  C12N15/52 ,  C07K14/435 ,  C12P21/00 ,  C07K14/485 ,  C07K14/475 ,  C07K14/495 ,  C07K14/525 ,  C07K14/54 ,  C07K14/56 ,  C07K14/61 ,  C07K14/745 ,  C07K16/28 ,  C07K16/40 ,  C12N9/02 ,  C12N9/12 ,  C12N9/68 ,  A61K38/00

CPC classification number: A61K48/0066 ,  A61K9/1271 ,  A61K9/145 ,  A61K9/5123 ,  A61K9/5146 ,  A61K9/5153 ,  A61K31/7115 ,  A61K38/00 ,  A61K38/17 ,  A61K38/177 ,  A61K38/1816 ,  A61K38/1891 ,  A61K38/191 ,  A61K38/193 ,  A61K38/212 ,  A61K38/45 ,  A61K38/4846 ,  A61K47/543 ,  A61K48/0033 ,  A61K48/005 ,  A61K48/0075 ,  C07H21/02 ,  C07K14/005 ,  C07K14/435 ,  C07K14/43595 ,  C07K14/47 ,  C07K14/4705 ,  C07K14/4713 ,  C07K14/4723 ,  C07K14/4746 ,  C07K14/475 ,  C07K14/485 ,  C07K14/495 ,  C07K14/505 ,  C07K14/515 ,  C07K14/525 ,  C07K14/535 ,  C07K14/5418 ,  C07K14/56 ,  C07K14/61 ,  C07K14/62 ,  C07K14/705 ,  C07K14/745 ,  C07K16/00 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/40 ,  C12N9/0069 ,  C12N9/0091 ,  C12N9/1051 ,  C12N9/1241 ,  C12N9/16 ,  C12N9/2402 ,  C12N9/2445 ,  C12N9/6435 ,  C12N9/6437 ,  C12N9/644 ,  C12N9/6443 ,  C12N9/6451 ,  C12N9/88 ,  C12N9/93 ,  C12N15/11 ,  C12N15/52 ,  C12N15/85 ,  C12N15/87 ,  C12P13/04 ,  C12P21/00 ,  C12P21/005 ,  C12Y113/12007 ,  C12Y116/03001 ,  C12Y207/07012 ,  C12Y304/21007 ,  C12Y304/21022 ,  C12Y304/21027 ,  C12Y403/02001 ,  C12Y603/02019 ,  Y02A50/401 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/415 ,  Y02A50/423 ,  Y02A50/463 ,  Y02A50/491

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

公开(公告)号：US11564998B2

公开(公告)日：2023-01-31

申请号：US16577734

申请日：2019-09-20

Applicant: ModernaTX, Inc.

Inventor： Antonin De Fougerolles ,  Justin Guild

IPC: A61K48/00 ,  C12N15/85 ,  C07K14/47 ,  C12N9/64 ,  C07K14/62 ,  A61K31/7115 ,  C12N9/88 ,  A61K9/127 ,  C12N15/11 ,  C07K14/705 ,  C07K14/505 ,  C07K14/535 ,  C12N9/10 ,  C12N9/00 ,  C12N9/42 ,  C12N15/87 ,  C12P13/04 ,  A61K38/45 ,  C07K14/005 ,  C12N9/16 ,  C12N9/24 ,  C12N15/52 ,  A61K38/17 ,  C07K14/435 ,  C12P21/00 ,  C07K14/485 ,  C07H21/02 ,  C07K14/475 ,  C07K14/495 ,  C07K14/525 ,  C07K14/54 ,  C07K14/56 ,  C07K14/61 ,  C07K14/745 ,  C07K16/28 ,  C07K16/40 ,  C12N9/02 ,  C12N9/12 ,  C12N9/68 ,  A61K47/54 ,  A61K9/14 ,  A61K9/51 ,  A61K38/18 ,  A61K38/19 ,  A61K38/21 ,  A61K38/48 ,  C07K14/515 ,  C07K16/00 ,  A61K38/00

Abstract: The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.

公开(公告)号：US10772975B2

公开(公告)日：2020-09-15

申请号：US15790246

申请日：2017-10-23

Applicant: ModernaTX, Inc.

Inventor： Stephane Bancel ,  Tirtha Chakraborty ,  Antonin De Fougerolles ,  Sayda M. Elbashir ,  Matthias John ,  Atanu Roy ,  Susan Whoriskey ,  Kristy M. Wood ,  Paul Hatala ,  Jason P. Schrum ,  Kenechi Ejebe ,  Jeff Lynn Ellsworth ,  Justin Guild

IPC: C07K14/535 ,  A61K38/17 ,  A61K48/00 ,  C12N15/85 ,  C07K14/47 ,  C07K14/62 ,  A61K31/7115 ,  C12N9/88 ,  A61K9/127 ,  C12N15/11 ,  C07K14/705 ,  C07K14/505 ,  C12N9/64 ,  C12N9/10 ,  C12N9/00 ,  C12N9/42 ,  C12N15/87 ,  C12P13/04 ,  A61K38/45 ,  C07K14/005 ,  C12N9/16 ,  C12N9/24 ,  C12N15/52 ,  C07K14/435 ,  C12P21/00 ,  C07K14/485 ,  C07H21/02 ,  C07K14/475 ,  C07K14/495 ,  C07K14/525 ,  C07K14/54 ,  C07K14/56 ,  C07K14/61 ,  C07K14/745 ,  C07K16/28 ,  C07K16/40 ,  C12N9/02 ,  C12N9/12 ,  C12N9/68 ,  A61K47/54 ,  A61K9/14 ,  A61K9/51 ,  A61K38/18 ,  A61K38/19 ,  A61K38/21 ,  A61K38/48 ,  C07K14/515 ,  C07K16/00 ,  A61K31/7088 ,  A61K47/10 ,  A61K38/00

Abstract: The invention relates to a pharmaceutical composition including a plurality of lipid nanoparticles having a mean particle size of between 80 nm and 160 nm and containing an mRNA encoding a polypeptide. The lipid nanoparticles include a cationic lipid, a neutral lipid, a cholesterol, and a PEG lipid. The mRNA contains a 5′-cap, 5′-UTR, a 3′-UTR, and a poly-A region with at least 100 nucleotides.

公开(公告)号：US10583203B2

公开(公告)日：2020-03-10

申请号：US16442168

申请日：2019-06-14

Applicant: ModernaTX, Inc.

Inventor： Antonin De Fougerolles ,  Justin Guild

IPC: A61K48/00 ,  A61K31/7115 ,  A61K38/17 ,  A61K47/54 ,  A61K9/127 ,  C07K14/005 ,  C12N15/11 ,  C12N9/00 ,  C12N15/85 ,  C07K14/62 ,  C07K14/47 ,  A61K38/19 ,  A61K38/18 ,  A61K9/51 ,  C12P21/00 ,  A61K9/14 ,  C07K16/00 ,  C07K14/515 ,  A61K38/48 ,  A61K38/21 ,  C12N9/64 ,  C07H21/02 ,  C07K14/435 ,  C07K14/475 ,  C07K14/495 ,  C07K14/525 ,  C07K14/54 ,  C07K14/56 ,  C07K14/61 ,  C07K14/745 ,  C07K16/28 ,  C07K16/40 ,  C12N9/02 ,  C12N9/12 ,  C12N9/68 ,  C12P13/04 ,  C12N15/87 ,  A61K38/45 ,  C12N9/24 ,  C12N9/16 ,  C07K14/535 ,  C07K14/505 ,  C07K14/705 ,  C12N15/52 ,  C12N9/42 ,  C12N9/10 ,  C07K14/485 ,  C12N9/88 ,  A61K38/00

Abstract: The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.

公开(公告)号：US10463751B2

公开(公告)日：2019-11-05

申请号：US15425645

申请日：2017-02-06

Applicant: ModernaTX, Inc.

Inventor： Antonin De Fougerolles ,  Justin Guild

IPC: A61K48/00 ,  A61K31/7115 ,  A61K38/17 ,  A61K47/54 ,  A61K9/127 ,  C07K14/005 ,  C12N15/11 ,  C12N9/00 ,  C12N15/85 ,  C07K14/47 ,  C07K14/62 ,  C12N9/88 ,  C07K14/705 ,  C07K14/505 ,  C07K14/535 ,  C12N9/64 ,  C12N9/10 ,  C12N9/42 ,  C12N15/87 ,  C12P13/04 ,  A61K38/45 ,  C12N9/16 ,  C12N9/24 ,  C12N15/52 ,  C07K14/435 ,  C12P21/00 ,  C07K14/485 ,  C07H21/02 ,  C07K14/475 ,  C07K14/495 ,  C07K14/525 ,  C07K14/54 ,  C07K14/56 ,  C07K14/61 ,  C07K14/745 ,  C07K16/28 ,  C07K16/40 ,  C12N9/02 ,  C12N9/12 ,  C12N9/68 ,  A61K9/14 ,  A61K9/51 ,  A61K38/18 ,  A61K38/19 ,  A61K38/21 ,  A61K38/48 ,  C07K14/515 ,  C07K16/00 ,  A61K38/00

Abstract: The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.

公开(公告)号：US10385106B2

公开(公告)日：2019-08-20

申请号：US14987328

申请日：2016-01-04

Applicant: ModernaTX, Inc.

Inventor： Antonin De Fougerolles ,  Justin Guild

IPC: A61K47/10 ,  A61K38/17 ,  A61K38/18 ,  A61K38/19 ,  A61K38/48 ,  A61K9/14 ,  C07K14/535 ,  A61K48/00 ,  A61K47/54 ,  C12N15/88 ,  A61K9/127 ,  A61K9/50 ,  A61K31/7088 ,  C07K19/00 ,  C12N15/85 ,  C07K14/47 ,  A61K38/21 ,  A61K38/36 ,  A61K38/44 ,  A61K39/395 ,  C07K14/475 ,  C07K14/505 ,  C07K14/525 ,  C07K14/56 ,  C07K14/565 ,  C07K14/745 ,  C07K14/75 ,  C07K16/28 ,  C07K16/32 ,  C12N9/02 ,  C12N9/64 ,  A61K9/00

Abstract: The present disclosure describes compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 5-methoxy-uridines to improve the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, protein half-life and/or modulation of a cell's status function, and/or activity.

公开(公告)号：US10323076B2

公开(公告)日：2019-06-18

申请号：US15026945

申请日：2014-10-03

Applicant: ModernaTX, Inc.

Inventor： Jeff Lynn Ellsworth ,  Joseph Beene Bolen ,  Francine M. Gregoire ,  Justin Guild

IPC: C07K14/705 ,  A61K38/00

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules encoding low density lipoprotein receptor comprising at least one mutation (e.g., an LDLR signally enhancing mutation).